For a psychiatrist or therapist, the 15 minutes after a patient leaves the room are often the most draining. That is the window for clinical documentation, a mandatory administrative task that contributes to the industry’s staggering burnout rates. Nextvisit AI, a pre-seed startup founded in 2021, is betting that passive, AI-driven note capture during the session itself can give that time back. The company’s early traction, reported at $9,000 in monthly recurring revenue from 68 paying customers, suggests a small but growing group of behavioral health providers are willing to test that promise [LinkedIn, 2025].
A wedge built on clinical nuance
Nextvisit’s product is an AI scribe that transcribes patient conversations in real time and automatically generates structured clinical notes, such as SOAP notes and intake documentation [Nextvisit.ai, 2025]. The core claim is that it is built exclusively for behavioral health. Co-founder Ryan Yannelli, a health technology engineer, has publicly outlined factors providers should evaluate, emphasizing the need for tools that understand the specific workflows and terminology of mental health care [Asbury Park Press, 2026]. The other co-founder, Dr. Faisal Rafiq, brings 15 years of practicing psychiatry to the product’s design [Doximity, 2026].
The early-stage foundation
The company’s foundation is characteristic of a very early venture. It graduated from Jason Calacanis’s LAUNCH Accelerator and has since joined Intercom’s startup program [Nextvisit Press Room, May 2025]. A $200,000 pre-seed round led by the LAUNCH Fund provides the initial capital [PitchBook, 2025]. The team remains small, estimated between two and ten employees.
| Role / Aspect | Detail |
|---|---|
| Co-Founder & Clinician | Dr. Faisal Rafiq, practicing psychiatrist with 15 years of experience |
| Co-Founder & CTO | Ryan Yannelli, software engineer with 15 years in health technology |
| Funding Stage | Pre-seed |
| Disclosed Funding | $200,000 |
| Key Investor | LAUNCH Fund |
The path from early adoption to clinical trust
The leap from a few dozen early adopters to widespread clinical use is formidable. Nextvisit’s public claims of being "trusted by 1,000+ health organizations" appear to refer to a broader user base, while the paying customer count sits at 68 [Nextvisit.ai, LinkedIn 2025]. The risks facing the company are acute in the heavily regulated healthcare sector.
- Clinical accuracy and liability. An AI-generated note that misses a critical detail is a potential clinical and legal liability.
- Regulatory navigation. Proactively engaging with FDA guidelines for Software as a Medical Device (SaMD) could become necessary.
- Integration and workflow. The tool’s value diminishes if it fails to integrate seamlessly with major electronic health record systems.
- Market competition. Larger, well-funded companies building general-purpose medical scribes could easily develop behavioral health modules.
Success for Nextvisit will depend on moving beyond a useful transcription tool to becoming an indispensable clinical partner. The next twelve months will likely focus on converting pilot programs into larger organizational contracts and beginning the long process of gathering clinical validation data.